Physician profile
James E Melott
NPI 1780680082
$1,750.25
in general payments reported to CMS, 2019-2025
21 companies · $99.54 in 2025
The $99.54 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $185 · 2021: $355 · 2022: $177 · 2023: $15.17 · 2024: $80.24 · 2025: $99.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.16 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.25 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $290.62 | 2019-2021 | |
| Amgen INC. | $240.66 | 2019-2021 | |
| Novo Nordisk INC | $160.55 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $127.81 | 2019-2023 | Shingrix |
| Astellas Pharma US INC | $121.03 | 2019-2024 | Veozah |
| Allergan, INC. | $107.09 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $65.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.11 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $46.21 | 2019-2021 | |
| Nevro Corp. | $42.57 | 2022 | |
| Lilly USA, LLC | $41.04 | 2020-2024 | Mounjaro |
| Amarin Pharma, INC. | $28.38 | 2019 | |
| Mylan Specialty L.P. | $20.97 | 2019 | |
| Si-Bone, INC. | $20.92 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $20.02 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $19.11 | 2019 | |
| Dynavax Technologies Corporation | $14.08 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $11.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.12 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Melott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.